Blogs & Articles - Page 10 of 14 - MarketsandMarkets Conferences

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

July 23, 2019July 23, 2019 MarketsandMarkets Conferences

London, UK July 23, 2019 – MarketsandMarkets recently interviewed Lorenzo Pasquali, Group Leader, Endocrine Regulatory Genomics Laboratory IGTP, Spain regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Lorenzo Pasquali is Group Leader of the Endocrine Regulatory Genomics laboratory at IGTP, Barcelona, Spain . His studies helped to map the epigenetic landscape of the insulin producing pancreatic islet cells resulting in milestone publications that opened the path to understand genomic regulation of the islets of Langerhans and shed…

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

July 15, 2019July 15, 2019 MarketsandMarkets Conferences

Washington D.C. [USA]: According to the Scientists, an autoimmune disease looks to be linked with testicular cancer that affects men. Known to us as ‘testicular cancer-associated paraneoplastic encephalitis’, it is the reason behind any serious neurological symptoms found in men. They lose control of the limbs, speech and eye movements progressively. The autoimmune disease starts with a testicular tumor, which seems to be the reason behind the immune system attacking the brain. Affected men find themselves undiagnosed or misdiagnosed often and relevant treatment is delayed. In a study that was published in…

Passage Bio on Producing Gene Therapies with Catalent’s Paragon

July 15, 2019 MarketsandMarkets Conferences

About five months ago Passage Bio that basically produces gene therapies for not so common monogenic CNS disease, in partnership with Catalent’s paragon launched a unit that is devoted to manufacturing suite Paragon Harman’s, MD, facility. The other cGMP suite whose worth is not being revealed yet is expected to hit it’s functional phase from mid-2020 and is support Passage Bio’s supply requirements from clinical through commercial phases. Stephen Squinto, P.hd, co-founder and Interim CEO at Passage Bio stated that “Passage will work contractually with Paragon to conduct GMP manufacturing…

Safety in Industry 4.0 – Are you prepared for the Automation?

July 10, 2019 MarketsandMarkets Conferences

With the rapid change of the modern world into an ‘Industry 4.0’ economy, it can be said that the change is somewhat similar to the Industrial revolution of the 18th century. Industries have undergone a significant change in terms of production and optimization of the whole process, things like machine learning; AI i.e. artificial intelligence and automation are the primary cause. As the process is getting better and mature there is the introduction of cyber-physical systems, cloud computing, and cognitive/behavioral computing all this gives rise to certain specific problems which…

Bravatek Solutions Signs Partnership Agreement for IIOT Technology

July 10, 2019July 10, 2019 MarketsandMarkets Conferences

AUSTIN, Texas, June 25, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Bravatek Solutions, Inc. (OTC Pink: BVTK) (“Bravatek” or the “Company”) declared that it entered into an arrangement with MC smart controls, Inc. to display and advertise its IIOT technology on an absolute basis to customers like policymakers and military. Along with this, BVTK will advertise its products on a non-absolute basis to manufacturers of systems that have a demand to be connected to the Internet. IIOT goes far beyond the regular customer devices because of its connection via communication…

Microba Partners with Korean Company Macrogen to Develop Global Microbiome Service Offering

July 9, 2019 MarketsandMarkets Conferences

Australian biotech giant Microba has made an alliance with Macrogen to develop microbiome research services for the offshore market. An MOU has got signed at the Macrogen Headquarters in Seoul on 14 March 2019 defining all the partnership terms and condition. Through this MOU, Macrogen and Microba will establish a close cooperation system. With this partnership, they will try to penetrate into the microbiome market of Korea and other nations Macrogen is a significant Korean company which has a market capitalization of 350m USD and annual revenues touching 100m USD….

Deal of Zymeworks up to $1.2bn Announced by J&J Biospecific Antibody

July 8, 2019 MarketsandMarkets Conferences

Johnson & Johnson and Zymeworks have done a deal by which Johnson & Johnson will pay Zymework $50m to license it as well as to develop around six therapeutic agents. Jansen will have all the ownership and responsibilities for all research development and commercialization of the outcome. According to Zymework’s CEO Ali Tehrani, the license is not exclusive for any targets. Zymeworks will receive a potential $282m in development and up to $1.12bn in milestone payments and royalties. Jansen has also the option to develop two additional bispecific programs subject…

The Bispecific and Complex mAbs Driving Process Development Innovation, Roche

July 4, 2019July 4, 2019 MarketsandMarkets Conferences

According to a statement by the VP of Roche technical development bioprocessing, Wolfgang Kuhne said that the older processes used to produce monoclonal antibodies like Herceptin and Avastin are not sufficient to produce complex and advanced pharmaceuticals. A bioprocess international European summit was held in Vienna, Austria during which delegates were told that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for Haemophilia last September – had required a considerable process development effort. In his statement, he clarified by saying “There are no more classical standard approaches…